FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311752793> ?p ?o ?g. }

• W4311752793 abstract "Abstract Background and Aims elevated Lipoprotein (a) levels are well recognized as a genetic risk factor for atherothrombotic events. Recently, new therapeutic approaches – such as small interfering RNA (siRNA) and antisense oligonucleotides (ASOs) – have been developed and are under evaluation in phase 3 trials. Evidences from literature suggest the need for screening Lp(a) in premature coronary artery disease. Aim of our study was to evaluate, in a real world scenario: 1) the percentage of premature CAD in whom clinicians choose to screen Lp(a); 2) the prevalence of hyperLp(a) in premature CAD. Methods we retrospectively evaluated data of patients admitted for acute coronary syndrome at Department of Cardiology of Careggi University Hospital, Florence, between 1st January 2018 and 31th July 2022. Inclusion criteria were: age &lt; 50 years for men and &lt; 55 years for women; confirmed diagnosis of acute coronary syndrome with obstructive coronary artery disease at hospital discharge. Results we selected 226 patients (50 F and 176 M; total median age 46 years, F median age 49 years, M median age 45 years). LDL median values at admission were 117.12 mg/dl). Nine out of 226 pts (3.9%) had LDL levels higher than 190 mg/dl, suggesting the possible diagnosis of Heterozygous Familial Hypercholesterolemia (with respect to the expected prevalence in the general population: 1/250 (0.004%). No patient had hepatic or thyroid disease. Sixty-eight out of 226 pts (30%) had triglycerides levels higher than 150 mg/dl; 41/226 (18.1%) with levels higher than 200 mg/dl. As regards Lp(a) levels, a dosage was performed in 93/226 patients (41.2%). We found that lipoprotein dosage was required more frequently in the 2020, 2021 and 2022 years (respectively in the 61%, 49% and 70% of patients) than in the 2018 and 2019 years (respectively in the 27% and 23% of patients) (Figure 1). Among patients in whom lipoprotein was dosed, elevated Lp(a) levels (&gt; 300 mg/L) were documented in 45/93 (48.4%). 15/93 (16.1%) patients had extreme elevated Lp(a) levels (&gt; 700 mg/L) (Figure 2). In two patients we documented both extreme Lp(a) levels and LDL levels higher than 190 mg/dl; in the other patients, elevated Lp(a) levels were the only lipid parameter out of range, and the only risk factor for premature CAD. By comparing these patients with an historical cohort of patients with ACS and age &gt;50 and 55 yrs in men and women respectively, we found at a multivariate analysis adjusted for classical risk factors that both elevated Lp(a) levels (OR:2.1 (95% CI 1.3–4.2), p&lt;0.005) and extreme elevated Lp(a) levels were significantly associated with the risk of premature CAD (OR: 1.8 (95% CI 1.4–3.9); p&lt;0.05). Conclusions these results demonstrated that: 1) it is urgent, from a clinical point of view, to apply screening protocols in premature CAD including Lp(a) dosage; 2) elevated Lp(a) levels, and in particular extreme elevated Lp(a) levels, have an elevated prevalence in a population of premature CAD and are significantly and independently associated with the disease." @default.
• W4311752793 created "2022-12-28" @default.
• W4311752793 creator A5004032203 @default.
• W4311752793 creator A5027242194 @default.
• W4311752793 creator A5031519448 @default.
• W4311752793 creator A5034593104 @default.
• W4311752793 creator A5043115715 @default.
• W4311752793 creator A5048659560 @default.
• W4311752793 creator A5052147463 @default.
• W4311752793 creator A5068485330 @default.
• W4311752793 creator A5068723999 @default.
• W4311752793 creator A5070057174 @default.
• W4311752793 creator A5074401377 @default.
• W4311752793 creator A5081721648 @default.
• W4311752793 date "2022-12-14" @default.
• W4311752793 modified "2023-10-18" @default.
• W4311752793 title "554 HYPERLIPOPROTEIN(A) AND PREMATURE CORONARY ARTERY DISEASE: A CALL FOR ACTION" @default.
• W4311752793 doi "https://doi.org/10.1093/eurheartjsupp/suac121.107" @default.
• W4311752793 hasPublicationYear "2022" @default.
• W4311752793 type Work @default.
• W4311752793 citedByCount "0" @default.
• W4311752793 crossrefType "journal-article" @default.
• W4311752793 hasAuthorship W4311752793A5004032203 @default.
• W4311752793 hasAuthorship W4311752793A5027242194 @default.
• W4311752793 hasAuthorship W4311752793A5031519448 @default.
• W4311752793 hasAuthorship W4311752793A5034593104 @default.
• W4311752793 hasAuthorship W4311752793A5043115715 @default.
• W4311752793 hasAuthorship W4311752793A5048659560 @default.
• W4311752793 hasAuthorship W4311752793A5052147463 @default.
• W4311752793 hasAuthorship W4311752793A5068485330 @default.
• W4311752793 hasAuthorship W4311752793A5068723999 @default.
• W4311752793 hasAuthorship W4311752793A5070057174 @default.
• W4311752793 hasAuthorship W4311752793A5074401377 @default.
• W4311752793 hasAuthorship W4311752793A5081721648 @default.
• W4311752793 hasBestOaLocation W43117527931 @default.
• W4311752793 hasConcept C126322002 @default.
• W4311752793 hasConcept C141071460 @default.
• W4311752793 hasConcept C164705383 @default.
• W4311752793 hasConcept C187212893 @default.
• W4311752793 hasConcept C2777698277 @default.
• W4311752793 hasConcept C2778163477 @default.
• W4311752793 hasConcept C2778213512 @default.
• W4311752793 hasConcept C2779120738 @default.
• W4311752793 hasConcept C2908647359 @default.
• W4311752793 hasConcept C500558357 @default.
• W4311752793 hasConcept C71924100 @default.
• W4311752793 hasConcept C99454951 @default.
• W4311752793 hasConceptScore W4311752793C126322002 @default.
• W4311752793 hasConceptScore W4311752793C141071460 @default.
• W4311752793 hasConceptScore W4311752793C164705383 @default.
• W4311752793 hasConceptScore W4311752793C187212893 @default.
• W4311752793 hasConceptScore W4311752793C2777698277 @default.
• W4311752793 hasConceptScore W4311752793C2778163477 @default.
• W4311752793 hasConceptScore W4311752793C2778213512 @default.
• W4311752793 hasConceptScore W4311752793C2779120738 @default.
• W4311752793 hasConceptScore W4311752793C2908647359 @default.
• W4311752793 hasConceptScore W4311752793C500558357 @default.
• W4311752793 hasConceptScore W4311752793C71924100 @default.
• W4311752793 hasConceptScore W4311752793C99454951 @default.
• W4311752793 hasIssue "Supplement_K" @default.
• W4311752793 hasLocation W43117527931 @default.
• W4311752793 hasOpenAccess W4311752793 @default.
• W4311752793 hasPrimaryLocation W43117527931 @default.
• W4311752793 hasRelatedWork W1969838637 @default.
• W4311752793 hasRelatedWork W2002120878 @default.
• W4311752793 hasRelatedWork W2003938723 @default.
• W4311752793 hasRelatedWork W2047967234 @default.
• W4311752793 hasRelatedWork W2072414940 @default.
• W4311752793 hasRelatedWork W2352815772 @default.
• W4311752793 hasRelatedWork W2439875401 @default.
• W4311752793 hasRelatedWork W2596796913 @default.
• W4311752793 hasRelatedWork W2888906357 @default.
• W4311752793 hasRelatedWork W2889407610 @default.
• W4311752793 hasVolume "24" @default.
• W4311752793 isParatext "false" @default.
• W4311752793 isRetracted "false" @default.
• W4311752793 workType "article" @default.